Vitalhub AI Stock Analysis
Vitalhub (6OVA) AI Stock Analysis
Vitalhub
(Frankfurt:6OVA)
No summary available
Vitalhub (6OVA) vs. iShares MSCI Germany ETF (EWG)
- Market Cap
- EUR 507.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 277
- Price to Earnings (P/E)
- 67.5
- Beta (1Y)
- 0.71
- Revenue Growth
- 45.02%
- EPS Growth
- 22.55%
- Country
- Germany
- Employees
- 700
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Vitalhub Business Overview & Revenue Model
Company Description
Vitalhub Corp., through its subsidiaries, provides innovative technological solutions to health and human service providers internationally, specifically catering to markets in Canada, the United States, the United Kingdom, Australia, and Western Asi...
Vitalhub Earnings Call Summary
The call presented multiple strong financial and operational positives: robust revenue growth (+33% YoY), exceeding the $100M ARR milestone (+10% organic ARR growth), improved adjusted EBITDA ($8.2M, +~30% YoY) and a healthy cash position (>$136M, no debt). Strategic progress includes near-complete integration of prior acquisitions, the Buddy Healthcare acquisition to expand digital patient engagement, active M&A pipeline, and ongoing AI product monetization efforts. The primary near-term headwinds are regional/regulatory uncertainty in the U.K. related to the Palantir/FTB situation that caused some suspended use and ARR reductions, modest gross margin compression (79% vs 81% prior year), and normal services revenue volatility. Overall, the highlights materially outweigh the lowlights, and the issues noted appear addressable or temporary.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Guidance from the call emphasized continued low double‑digit organic ARR growth (running ~10–11% this year), with ARR at $101.5M as of June 30 (pro forma ~$106M including Buddy Healthcare), Q2 revenue of $31.7M (+33% YoY), recurring revenue $24.5M (77% of sales), virtual care term license $2.3M, perpetual license $0.8M, services/hardware $4.1M, gross margin ~79%, adjusted EBITDA $8.2M (26% margin) and a goal to push adjusted EBITDA into the high‑20s; strong cash position ($136.5M cash & investments, no debt, cash up >$15M in the quarter and >$120M available post‑Buddy) supports both continued M&A activity and a NCIB (board signaled potential buybacks up to ~5%), while AI/transcription products are expected to begin contributing revenue late 2026 into 2027.
Vitalhub Peers Comparison
Overall Rating
TSE:NDAT45Neutral
TSE:ADK43Neutral
TSE:UDOC39Underperform
TSE:CHS37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:NDAT | 45Neutral | CAD 2.07M | -16.67 | -49.83% | ― | ― | 0.00% |
| TSE:ADK | 43Neutral | CAD 42.14M | -8.47 | 9999.00% | ― | -36.92% | 13.03% |
| TSE:UDOC | 39Underperform | CAD 3.89M | -1.19 | 355.56% | ― | 614.03% | 51.97% |
| TSE:CHS | 37Underperform | CAD 8.70M | -1.47 | 64.52% | ― | 7.63% | -106.03% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DE:6OVA | Vitalhub Corp. | 4.58 | -1.12 | -19.65% | |
| TSE:ADK | Diagnos Inc | 0.35 | 0.07 | 25.00% | |
| TSE:NDAT | nDatalyze Corp | 0.05 | 0.04 | 233.33% | |
| TSE:CHS | Comprehensive Healthcare Systems Inc | 0.31 | -0.20 | -39.22% | |
| TSE:UDOC | Unidoc Health Corp. | 0.04 | -0.16 | -78.57% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.